
Fabry Disease Treatments Compared
3 FDA-approved drugs, plus 2 in development, side by side from the current prescribing labels. Newest label Aug 2025. Checked November 3, 2026.
The full Fabry Disease guide, with open trials and help paying →
Three drugs are FDA-approved for Fabry disease, 2 enzyme replacement infusions and 1 capsule.
- Fabrazyme (agalsidase beta) and Elfabrio (pegunigalsidase alfa) are infusions given every 2 weeks.
- Galafold (migalastat) is a capsule taken every other day, approved only for people whose GLA gene variant is amenable to it.
- Fabrazyme is the only one approved for children, from age 2; Elfabrio and Galafold are for adults.
- Elfabrio is the only drug tested head to head, against Fabrazyme in people already taking it, and kidney function declined at nearly the same rate on both over 2 years.
- Both infusions carry a boxed warning for severe allergic reactions including anaphylaxis. Galafold has no boxed warning, holds accelerated approval and is not recommended with severe kidney impairment.
Latest for Fabry disease
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial sitesFewer sites now listed for Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and… (Phase 3, Sanofi)ClinicalTrials.gov
Free email alert
Email me the day the FDA decides on ST-920
You get one email when the decision is public, plus new trials and FDA news for this condition.
You'll get trial alerts and disease updates for Fabry Disease, and you can turn either off anytime. We never share your email. Privacy policy
3 approved Fabry disease treatments at a glance
How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.
A year on each Fabry disease treatment
Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.
Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.
What the pivotal Fabry disease trials showed
The primary result from the trial each FDA approval rests on, as reported on the label.
Fabry Disease treatment side effects and warnings
Fabrazyme and Elfabrio carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.
Fabry disease treatments in Phase 3 or under FDA review
Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.
Help paying for Fabry disease treatment
Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.
One email when the FDA acts on a Fabry Disease treatment, a label changes or a new trial opens. Never a newsletter.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Fabry Disease treatment questions people ask
Fabrazyme vs Elfabrio: what is the difference for Fabry disease?
Both replace the missing alpha-galactosidase A enzyme by IV infusion every 2 weeks at 1mg/kg. Elfabrio is a newer version of the enzyme, made in plant cells and linked to PEG, a coating used to change how a drug behaves in the body.
Who it is for: Fabrazyme covers adults and children 2 and older. Elfabrio covers adults only.
Trial results: Elfabrio is the only Fabry drug tested head to head. In 77 adults already on Fabrazyme, kidney function declined 2.4mL/min per year on Elfabrio and 2.3 on Fabrazyme over 2 years, a difference of 0.1.
Safety: both carry a boxed warning for anaphylaxis. Elfabrio's label also warns about membranoproliferative glomerulonephritis, a kidney inflammation reported in 1 trial patient, and calls for regular kidney tests. Infusion reactions were reported in 32% of people on each drug in the head-to-head trial.
Switching: Elfabrio's label includes starting infusion rates for people coming from another enzyme replacement therapy. Whether to switch is a decision for the treating doctor.
More: Fabrazyme drug page and Elfabrio drug page
Source: FDA label for Fabrazyme, DailyMed, effective August 2025; FDA label for Elfabrio, DailyMed, effective July 2024
Who can take Galafold for Fabry disease?
Adults with confirmed Fabry disease and a GLA gene variant that a lab assay shows is amenable to migalastat. The label recommends a clinical genetics professional review the variant when its meaning is uncertain. Galafold is not recommended for people with severe kidney impairment (eGFR below 30) or on dialysis, and it is not approved for children. It is taken as 1 capsule every other day with no food or caffeine for 2 hours before and after.
Is there a pill for Fabry disease?
Yes, Galafold (migalastat), but only for adults with an amenable GLA variant. Two other pills have reached Phase 3, venglustat from Sanofi and lucerastat from Idorsia. Sanofi said on July 30, 2026 that venglustat missed the main goal of its Phase 3 heart trial, CARAT, after its PERIDOT pain trial missed in February 2026, and that long-term extensions of both trials continue. Sanofi's July 30, 2026 results slides list venglustat for Fabry as removed from its Phase 3 pipeline. Lucerastat's new Phase 3 trial, Fab-Klear (NCT07778667), is enrolling at a Dallas site as of November 2026.
Which Fabry disease treatment is approved for children?
Only Fabrazyme, approved from age 2 since March 2021. Elfabrio and Galafold are approved for adults. Both have pediatric studies recruiting: Elfabrio in children (NCT06328608) and Galafold in children aged 2 to under 12 (NCT06904261).
Are there new Fabry disease treatments in clinical trials?
As of November 2026, the oral drug with an open Phase 3 trial is lucerastat from Idorsia, whose study (NCT07778667) plans about 16 untreated adult men and is enrolling at a Dallas site. Venglustat, an oral drug from Sanofi, missed the main goal of both of its Phase 3 Fabry trials, PERIDOT in February 2026 and CARAT, a heart trial in 104 adults, in results Sanofi reported on July 30, 2026, and long-term extensions of both continue. Sanofi's results slides that day list venglustat for Fabry as removed from its Phase 3 pipeline. ST-920, a one-time gene therapy now owned by PTC Therapeutics, finished its Phase 1/2 trial (NCT04046224), and PTC said on October 29, 2026 that it expects to finish submitting its FDA application in the fourth quarter of 2026. AMT-191, a gene therapy from uniQure, is in a recruiting Phase 1/2 trial (NCT06270316). The 4D-310 gene therapy from 4D Molecular Therapeutics still has a Phase 1/2 record marked recruiting (NCT05629559), but that record was last updated in February 2025 and 4DMT no longer lists 4D-310 on its pipeline page.
Does Fabrazyme slow kidney decline in Fabry disease?
Its label reports 2 kinds of evidence. In a trial of 82 people with more advanced disease, kidney, heart or stroke events or death occurred in 28% on Fabrazyme against 42% on placebo, a difference that was not statistically certain. In an observational comparison of 122 treated people with matched untreated patients, kidney function declined 1.5mL/min per year on Fabrazyme against 3.2 untreated.
More on Fabry Disease at Trial Friend
Where every number on this page comes from
Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.
- Fabrazyme (agalsidase beta) prescribing information, Sanofi (Genzyme), label dated Aug 2025. DailyMed
- Elfabrio (pegunigalsidase alfa) prescribing information, Chiesi (developed with Protalix), label dated Jul 2024. DailyMed. Pivotal trial: ClinicalTrials.gov
- Galafold (migalastat) prescribing information, Amicus Therapeutics (BioMarin), label dated Aug 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
- venglustat, Sanofi: ClinicalTrials.gov record; Sanofi Q2 2026 results press release, July 30, 2026. Checked November 3, 2026.
- ST-920 (isaralgagene civaparvovec), PTC Therapeutics (developed by Sangamo Therapeutics): ClinicalTrials.gov record; PTC Therapeutics Q3 2026 results press release, October 29, 2026. Checked November 8, 2026.
This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.